Results 71 to 80 of about 12,110 (254)

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Frontiers in Psychiatry, 2020
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders.
Juan José Fuentes, Francina Fonseca, Francina Fonseca, Francina Fonseca, Matilde Elices, Matilde Elices, Magí Farré, Magí Farré, Marta Torrens, Marta Torrens, Marta Torrens   +10 more
doaj   +1 more source

Immunoassay Analysis of Lysergic Acid Diethylamide [PDF]

Journal of Analytical Toxicology, 1997
Screening large numbers of urine samples for drugs of abuse is typically accomplished using immunoassays that allow for processing large numbers of samples without the requirement of sample preparation before analysis. Until fairly recently, screening of lysergic acid diethylamide (LSD) in urine samples could only be accomplished by the use of ...
J T, Cody, S, Valtier
openaire   +2 more sources

Substance use in the club scene of Rome : a pilot study [PDF]

, 2014
Date of Acceptance: 28/08/2014 Copyright © 2014 Alessandro Emiliano Vento et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium ...
Acciavatti, Tiziano, Bonifaci, Ludovica, Carrus, Dario, Chillemi, Eleonora, Cinosi, Eduardo, Corazza, Ornella, di Giannantonio, Massimo, Lupi, Matteo, Martinotti, Giovanni, Santacroce, Rita, Schifano, Fabrizio, Vento, Alessandro   +11 more
core   +4 more sources

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT2A-serotonin receptors in the brain.
Joachim Neumann, Stefan Dhein, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs   +4 more
doaj   +1 more source

A mood disorder episode with an onset under chronic cannabis consumption and accompanied with psychotic features immediately after N, N-Dimethyltryptamine (DMT) use: a case report [PDF]

Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi, 2011
, N-dimethyltryptamine (DMT) is a serotonin agonist hallucinogen, similar to lysergic acid diethylamide (LSD). Syntetic production of DMT as well as extraction from several plants of South American flora is possible.
Güliz Özgen, İlker Küçükparlak, Gökhan Umut, Ahmet Türkcan   +3 more
doaj  

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

A non-hallucinogenic LSD analog with therapeutic potential for mood disorders

Cell Reports, 2023
Summary: Hallucinations limit widespread therapeutic use of psychedelics as rapidly acting antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at more than 33 aminergic G protein-coupled
Vern Lewis, Emma M. Bonniwell, Janelle K. Lanham, Abdi Ghaffari, Hooshmand Sheshbaradaran, Andrew B. Cao, Maggie M. Calkins, Mario Alberto Bautista-Carro, Emily Arsenault, Andre Telfer, Fatimeh-Frouh Taghavi-Abkuh, Nicholas J. Malcolm, Fatema El Sayegh, Alfonso Abizaid, Yasmin Schmid, Kathleen Morton, Adam L. Halberstadt, Argel Aguilar-Valles, John D. McCorvy   +18 more
doaj   +1 more source

Novel Psychoactive Substances 14Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs [PDF]

, 2017
A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psychoactive effects.
Boris B. , Quednow, Christian P. , Müller, Erich, Seifritz, Hassan, Zurina, Johannes, Kornhuber, Kasinather, B. Vicknasingam, Narayanan, Suresh, Oliver G., Bosch, Singh, Darshan   +8 more
core   +1 more source